The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal <i>IκB</i> and <i>CD11b</i> gene expression in mice
-
- Abbas Muzaffar
- Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University
-
- Alzarea Sami
- Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University
-
- Papke Roger L
- Department of Pharmacology and Therapeutics, University of Florida
-
- Rahman Shafiqur
- Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University
この論文をさがす
抄録
<p>We have reported that 3a,4,5,9b-tetrahydro-4-(1-naphthalenyl)-3H-cyclopentan[c]quinoline-8-sulfonamide (TQS), α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator (PAM) reduces lipopolysaccharide (LPS)-induced hyperalgesia and allodynia in mice. The objective of the present study was to determine the effects of TQS on LPS-induced activation of hippocampal inhibitor of κB (IκB) and cluster of differentiation 11b (CD11b) gene expression involving hyperalgesia and allodynia in mice. We also examined the effects of TQS on microglial phenotype following LPS administration. Pretreatment of TQS (4 mg/kg) reduced the expressions of IκB and CD11b mRNA. Pretreatment of methyllycaconitine (3 mg/kg), an α7 nAChR antagonist, reversed TQS-induced decrease in IκB and CD11b mRNA expressions in the hippocampus indicating the involvement of α7 nAChR. In addition, TQS (4 mg/kg) reversed the LPS-induced microglial morphological changes. These results suggest that TQS reduces LPS-induced IκB and CD11b gene expression and microglial activation associated with hyperalgesia and allodynia by targeting microglial α7 nAChR in the hippocampus.</p>
収録刊行物
-
- Drug Discoveries & Therapeutics
-
Drug Discoveries & Therapeutics 11 (4), 206-211, 2017
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会